We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 41,122

Sanofi seeks IPR of Cabilly patent
  • Foley & Lardner LLP
  • USA
  • July 30 2015

On July 27, 2015, Sanofi-aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. filed a petition for Inter Partes Review (IPR) of the “Cabilly II”


Louisiana federal district court ruling turns the duty to preserve evidence on its head
  • Dentons
  • USA
  • July 30 2015

In 2014, a Louisiana federal district court jury decided that two pharmaceutical companies should pay a staggering $9 billion in punitive damages (6


The PSQIAAmendment 7 debate in preparation for Charles
  • Roig Lawyers
  • USA
  • July 30 2015

In a storm of acronyms that has been brewing since 2005, the First District Court of Appeal is set to rule on the interaction of Florida's "Amendment


Happy 50th birthday Medicare and Medicaid: midlife crisis or the golden years?
  • Hall Render Killian Heath & Lyman PC
  • USA
  • July 30 2015

On July 30, 1965, President Lyndon B. Johnson signed into law what we now know as the Medicare and Medicaid programs. They came into being after a


The corporate practice prohibition in New York: what we can learn from the ADMI settlement
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • July 30 2015

One of the most frequently asked questions posed to healthcare lawyers is whether State X has a prohibition on the corporate practice of medicine


White House releases draft privacy principles for the Precision Medicine Initiative
  • McDermott Will & Emery
  • USA
  • July 30 2015

Six months after the Precision Medicine Initiative’s (Initiative’s) debut, the White House has released a working draft of proposed privacy and trust


Obviousness inquiry for ocular patents not mis-framed
  • McDermott Will & Emery
  • USA
  • July 30 2015

Affirming the finding by the U.S. District Court for the District of New Jersey that defendant failed to prove Plaintiffs’ patents directed to


Federal Circuit relaxes limits of safe harbor for post-approval studies
  • McDermott Will & Emery
  • USA
  • July 30 2015

Affirming the U.S. District Court for the District of Maryland, the U.S. Court of Appeals for the Federal Circuit recently held the “safe harbor”


Reverse payment settlements subject to antitrust challenge
  • McDermott Will & Emery
  • USA
  • July 30 2015

In a class action case assessing the implications of antitrust law in a patent infringement and validity settlement agreement, the Supreme Court of


Supreme Court holds good faith belief of patent invalidity is not a defense to induced infringement
  • McDermott Will & Emery
  • USA
  • July 30 2015

Pharmaceutical patents commonly include claims directed to methods of treatment using a purportedly novel compound, formulation or treatment regimen